Objective: To explore the intervention value of pharmaceutical care pathway management on medication utilization rate in patients with acute coronary syndrome (ACS). Method: A total of 124 inpatient ACS patients admitted to our hospital from January 2020 to December 2021 were selected as the research subjects, of which 62 patients were admitted from January 2020 to December 2020 as the control group, and routine drug treatment management was implemented in 2021. From January to December 2021, 62 patients were admitted as the experimental group, and the management of pharmaceutical care pathways was implemented. The drug usage rate, treatment target compliance rate, incidence of adverse reactions, and common medication problems were analyzed in the two groups. Results: After the implementation of pharmaceutical care pathway management, the number of problems related to indications, effi cacy and safety during drug treatment in the experimental group was signifi cantly lower than that in the control group (P＜0.05); the full score rate of drug knowledge awareness in the experimental group was higher than that in the control group (P＜0.05); the use rate of secondary preventive drugs such as β-receptor blockers, angiotensin converting enzyme inhibitors/angiotensin receptor blockers (ACEI/ARB) was higher than that of the control group (P＜0.05); the use rate of secondary preventive drugs in the experimental group was higher than that in the control group (P＜0.05). Lower than the control group (P＜0.05); the readmission rate of patients in the experimental group at 6 months was lower than that in the control group (P＜0.05). Conclusion: The use of pharmaceutical care pathway management for patients with ACS can eff ectively reduce the problem of drug use, improve the safety and eff ectiveness of drug treatment, increase the utilization rate of secondary prevention drugs, and achieve better drug control eff ect.
Cai Liwen, Zhang Bin, Wang Xinyu
. Study on Intervention Value of Pharmaceutical Care Pathway Management on Drug Use Rate in Patients with Acute Coronary Syndrome[J]. Chinese Pharmaceutical Affairs, 2023
, 37(9)
: 1074
-1082
.
DOI: 10.16153/j.1002-7777.2023.09.012
[1] Kamran H，Jneid H，Kayani WT，et al.Oral Antiplatelet Ttherapy After Acute Coronary Syndrome：a Review[J].Jama，2021，325（15）：1545-1555.
[2] 顾倩，李春坚.急性冠状动脉综合征患者经皮冠状动脉介入治疗术后出血风险评估[J].中国介入心脏病学杂志，2021，29（12）：689-694.
[3] Nicholls SJ，Schwartz GG，Buhr KA，et al.Apabetalone and Hospitalization for Heart Failure in Patients Following an Acute Coronary Syndrome：a Prespecified Analysis of the Bet on Mace study[J].Cardiovascular diabetology，2021，20（1）：1-9.
[4] 张海涛，王春玥，叶绍东，等.淋巴瘤合并非急性冠状动脉综合征冠心病患者的长期预后分析：一项单中心回顾性研究[J].岭南心血管病杂志，2020，26（4）：377-380.
[5] Hauguel-Moreau M，Pillière R，Prati G，et al.Impact of Coronavirus Disease 2019 Outbreak on Acute Coronary Syndrome Admissions：Four Weeks to Reverse the Trend[J].Journal of Thrombosis and Thrombolysis，2021，51（1）：31-32.
[6] 张永娜，张艳娇，赵莉，等.1例冠状动脉旁路移植术后肝素诱导血小板减少症患者药物治疗与药学监护[J].中国药物警戒，2021，18（3）：284-288.
[7] Kim WK，Pellegrini C，Ludwig S，et al.Feasibility of Coronary Access in Patients with Acute Coronary Syndrome and Previous TAVR[J].Cardiovascular Interventions，2021，14（14）：1578-1590.
[8] Sawano M，Kohsaka S，Ishii H，et al.One-Year Outcome After Percutaneous Coronary Intervention for Acute Coronary Syndrome-An Analysis of 20，042 Patients From a Japanese Nationwide Registry[J].Circulation Journal，2021，85（10）：1756-1767.
[9] 张雪峰，彭云云，盛国华，等.延伸性抗凝药学监护对房颤并PCI手术患者临床效应的影响[J].药学与临床研究，2021，29（6）：444-448.
[10] Matsushita K，Hess S，Marchandot B，et al.Clinical Features of Patients with Acute Coronary Syndrome During the COVID-19 Pandemic[J].Journal of Thrombosis and Thrombolysis，2021，52（1）：95-104.
[11] 王霁宁，张芸婷，李冬洁.1例冠脉造影术后出血房颤患者的药学监护及用药分析[J].中国药师，2021，24（7）：331-334.
[12] Opstal TSJ，Fiolet ATL，van Broekhoven A，et al.Colchicine in Patients with Chronic Coronary Disease in Relation to Prior Acute Coronary Syndrome[J].Journal of the American College of Cardiology，2021，78（9）：859-866.
[13] 陈丹，张喆，姚晨.1例低密度脂蛋白胆固醇水平极低的急性冠脉综合征患者他汀类药物治疗的药学监护[J].中国临床药学杂志，2020，29（2）：146-149.
[14] Coughlan JJ，Aytekin A，Lahu S，et al.Ticagrelor or Prasugrel for Patients with Acute Coronary Syndrome Treated with Percutaneous Coronary Intervention：a Prespecified Subgroup Analysis of a Randomized Clinical Trial[J].JAMA cardiology，2021，6（10）：1121-1129.
[15] 西娜，张国庆.PCI术后抗血小板药物抵抗患者的药学监护切入点[J].中南药学，2020，18（4）：702-705.
[16] Galli M，Benenati S，Franchi F，et al.Comparative Effects of Guided vs.Potent P2Y12 Inhibitor Therapy in Acute Coronary Syndrome：a Network Meta-analysis of 61 898 Ppatients from 15 Randomized Trials[J].European Heart Journal，2022，43（10）：959-967.
[17] 吕达娜.缺血性脑卒中合并慢性肾功能不全患者降糖方案优化的药学监护[J].中国药物应用与监测，2020，17（4）：242-245.
[18] 唐宗伟，李琴.1例PCI术后消化系统出血患者抗栓药物管理与药学监护[J].中国药师，2021，24（1）：113-116.
